Catalent pushes into gene therapy with $1.2 bln buyout of Paragon Bioservices

April 15 () - Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments.

Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing and manufacturing products such as complex biopharmaceuticals for its clients.

Catalent also develops drugs for other companies and does business in Asia, Europe, and North and South America.

In Februray, Swiss drugmaker Roche agreed to buy U.S.-based gene therapy specialist Spark Therapeutics Inc for $4.3 billion, while Novartis purchased U.S.-based Avexis for $8.7 billion last year.

Catalent expects the transaction to add to its adjusted earnings in the second full fiscal year after closing.

The company said it will fund the deal with proceeds from a $650 million incremental term loan and issuance of $650 million of a new series of convertible preferred stock.

After the deal closes, Paragon will be led by its Chief Executive Officer Pete Buzy.

The Wall Street Journal reported on Sunday that Catalent had agreed to buy Paragon.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

Stocks World Markets

Latest Politics Videos


Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More